Navigation Links
Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
Date:10/10/2008

MADISON, N.J., Oct. 10 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that the jury in the case of Danny Crowder (Individually and as Administrator of the Estate of Edna Faye Crowder) v. Wyeth in the Philadelphia Court of Common Pleas found in favor of Wyeth.

"We believe this unanimous verdict was supported by the evidence," says Bob Nicholas, an attorney from Reed Smith, who represented Wyeth. "While Mrs. Crowder's death was tragic, the medical evidence clearly demonstrated that her condition was unrelated to the diet drugs she used over ten years ago."

The trial began on September 29, 2008 before The Honorable Gary S. Glazer. The plaintiff alleged the wrongful death of Mrs. Crowder caused by Primary Pulmonary Hypertension (PPH) as a result of her use of the diet drug Pondimin(R), a drug once marketed by Wyeth. The Court had earlier ruled that plaintiff could not pursue punitive damages in this case.

The plaintiff was represented by the Clark Burnett law firm of Houston, Texas.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Wyeth Announces Increase in Common Stock Dividend
2. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
3. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
4. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
5. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
6. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
7. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
8. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
9. Wyeth Declares Common and Preferred Stock Dividends
10. Wyeth Pharmaceuticals Announces Organizational Change
11. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Sept. 18, 2017   Montrium , a growing leader ... exciting new partnership with a groundbreaking non-profit research organization, Multidisciplinary ... ... psychotherapy studies for PTSD ... recently granted Breakthrough Therapy Designation to MDMA for the treatment of ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... pharma and biotech at the third annual DrugDev Summit, November 7-8, 2017 in ... the world’s most progressive clinical research leaders for best practice case studies, keynote ...
(Date:9/14/2017)... (PRWEB) , ... September 14, 2017 , ... AIM Global, ... Medical Tracking Systems Inc. has won the 2017 Case Study Competition for AIDC. ... which provide benefits that decrease risk” and push the adoption of automated data collection ...
(Date:9/12/2017)... Brunswick, NJ (PRWEB) , ... September 12, 2017 ... ... one of the fastest growing b2b product testing and development companies will be ... expanded service offerings. , Contract Pharma is an educational ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
Breaking Biology News(10 mins):